NLSP's Business Model
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://nlspharma.com |
| CEO (Chief Executive Officer) | Alexander Zwyer |
| Number of Employees | |
| IPO date | January 29, 2021 |
NLSP Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | CH |
| Address | The Circle 6 |
| City | Zurich |
| State | None |
| Phone | 41 44 512 21 50 |
| Zip Code | 8058 |
| Other Identifiers | |
| CIK | 0001783036 |
| ISIN | CHH5835A1095 |
| CUSIP | H5835A109 |
| Open | 3.31 |
| Previous Close | 3.33 |
| Volume | 114 Thou. |
| Average Volume | 74.12 Thou. |
| Day’s Range | 2.91 – 3.51 |
| 52 Week Range | 0.76-43.4 |
| MA (50) | 18.9882 |
| MA (200) | 19.4041 |
| Market Cap | 919.6 Thou. |
| Shares Out. | 316 Thou. |
| Earnings Date | Feb 25, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
